Month 31 – Quiet Month

On By DanIn Prostate CancerLeave a comment

It’s been a quiet month this month, so there’s really not much to report.  That’s good.

I decided it was time to get a bit more physically active, so I’ve started doing some fitness walking.  And, while I’m in the early stages of it and my legs are a bit sore, I’m happy to report that there hasn’t been any problems with leakage as I’m speeding through the neighborhood.  (This morning I walked 4 miles in one hour–not bad for being 9 days into this.)

So, aside from my earlier special posts, that’s about it for this month.

Special Post – Safeway and Vons Support PCa Research and Awareness in June

On By DanIn Prostate CancerLeave a comment

I normally don’t like to plug specific companies, but when they go out of their way to increase prostate cancer awareness and help fund much needed research, I feel obligated to support them in their efforts.

Once again, during the month of June, the Safeway / Vons chains of supermarkets are asking customers to round up their purchase to the nearest dollar–or to make a larger donation–to help fight prostate cancer.

You can read about their efforts and where the money is going here:

Safeway Foundation

Press Release

Special Post – PSA Results

On By DanIn Prostate CancerLeave a comment

My PSA remains <0.01 (undetectable) 28 months after my surgery.  Translation: Still cancer-free.  Woo-hoo!

I asked my urologist about the recent studies that came out and the AUA’s recommendations for PSA tests going forward, and his reaction was interesting.  I’m not sure that he’s fully convinced that reducing screening is the right thing to do.  Still, he seemed open to the new thought process on the issue.

If anything, it told me that this discussion is far from over.

Month 30 – Genetic Test & PSA Guidance

On By DanIn Diagnosis, Prostate Cancer, ResearchLeave a comment

This will be a long post because there have been several important stories in the news about prostate cancer recently.

*    *    *

The first report talks about a new genetic test that will better classify the aggressiveness of prostate cancer, and that will allow patients and their physicians to better guide their treatment decision.  This progress is quite exciting.

New Test May Help Guide Prostate Cancer Treatment 
(Full text below in case article gets deleted by NBC News.)

Being able to know the aggressiveness of the cancer may give men on active surveillance greater peace of mind, and it may allow those who are recently diagnosed to choose active surveillance as their treatment option, avoiding the potential risks of long-term, significant side effects that can come with radiation or surgery.

Of course, the test is new and unproven in the real world yet.  Still, it is a step in the right direction.

The second article talks about the American Urological Association’s (AUA) change in guidelines concerning PSA testing, making the testing less frequent.

Urologists Recommend Less PSA Testing for Prostate Cancer
(Full text below in case article gets deleted by NPR.)

Funny that this article about PSA screenings would come out just before my next post-operative PSA screening (scheduled to get the results on 20 May).  I’ll have to ask my urologist what his thoughts are on all this.

*    *    *

What do I think about all of this?  Well, I’m glad that there is more and more research that is bringing the diagnosis and treatment of prostate cancer into better focus.  Don’t get me wrong, I still think there’s a long way to go, and if prostate cancer research had half the attention and support that breast cancer research does, we could make so much more progress at a more rapid pace.

What would I do if I were diagnosed with prostate cancer today given these and other recent developments in prostate cancer diagnosis, classification, and treatment?  Would I have skipped the radical prostatectomy?  I don’t know.

What likely would have happened is that I would have slowed the decision-making process down to allow for more time for research and reflection.

When you hear “cancer” for the first time, your immediate response is to say, “Get rid of it!”  That’s they way we’ve been conditioned all of our lives.  But now with these advances, we’re getting to the point where the initial response can be, “Can I live with it?”  But it’s going to take researchers and the medical community considerable time, effort, and facts to convince us that “Can I live with it?” should be the appropriate response.

*     *     *
Pricey new test may help guide prostate cancer treatment
By MARILYNN MARCHIONE
updated 5/8/2013 9:55:14 AM ET 2013-05-08T13:55:14
A new genetic test to gauge the aggressiveness of prostate cancer may help tens of thousands of men each year decide whether they need to treat their cancer right away or can safely monitor it.
The new test, which goes on sale Wednesday, joins another one that recently came on the market. Both analyze multiple genes in a biopsy sample and give a score for aggressiveness, similar to tests used now for certain breast and colon cancers.
Doctors say tests like these have the potential to curb a major problem in cancer care — overtreatment. Prostate tumors usually grow so slowly they will never threaten a man’s life, but some prove fatal and there is no reliable way now to tell which ones will. Treatment with surgery, radiation or hormone blockers isn’t needed in most cases and can cause impotence or incontinence, yet most men are afraid to skip it.
“We’re not giving patients enough information to make their decision,” said Dr. Peter Carroll, chairman of urology at the University of California, San Francisco. “You can shop for a toaster” better than for prostate treatment, he said.
A study he led of the newest test — the Oncotype DX Genomic Prostate Score — is set for discussion Wednesday at an American Urological Association meeting in San Diego.
The results suggest the test could triple the number of men thought to be at such low risk for aggressive disease that monitoring is a clearly safe option. Conversely, the test also suggested some tumors were more aggressive than doctors had believed.
Independent experts say such a test is desperately needed but that it’s unclear how much information this one adds or whether it will be enough to persuade men with low-risk tumors to forgo treatment, and treat it only if it gets worse. Only 10 percent who are candidates for monitoring choose it now.
“The question is, what’s the magnitude of difference that would change the patient’s mind?” said Dr. Bruce Roth, a cancer specialist at Washington University in St. Louis.
One man may view a 15 percent chance that his tumor is aggressive as low risk “but someone else might say, ‘Oh my God, let’s set the surgery up tomorrow,'” he said. “I don’t think it’s a slam dunk.”
Also unknown: Will insurers pay for the expensive test without evidence it leads to better care or saves lives?
The newest test was developed by Genomic Health Inc., which has sold a similar one for breast cancer since 2004. Doctors at first were leery of it until studies in more groups of women proved its value, and the same may happen with the prostate test, said Dr. Len Lichtenfeld, the American Cancer Society’s deputy chief medical officer.
The company will charge $3,820 for the prostate test and says it can save money by avoiding costlier, unnecessary treatment. Another test for assessing prostate cancer risk that came out last summer — Prolaris by Myriad Genetics Inc. — sells for $3,400.
Both companies can sell the tests without Food and Drug Administration approval under separate rules that govern lab diagnostics. Myriad Genetics has published nine studies on Prolaris involving more than 3,000 patients. Genomic Health has not published any results on the prostate test, another thing that makes doctors wary. Yet it has a track record from its breast cancer test.
About 240,000 men in the U.S. are diagnosed with prostate cancer each year, and about half are classified as low risk using current methods. Doctors now base risk estimates on factors such as a man’s age and how aggressive cells look from biopsies that give 12 to 14 tissue samples. But tumors often are spread out and vary from one spot to the other.
“Unless you can be sure your biopsy has hit the most aggressive part that’s in the prostate, you can’t be sure” how accurate your risk estimate is, explained Dr. Eric Klein, chief of urology at the Cleveland Clinic, who led early development of the Oncotype prostate cancer test.
For one study, researchers used prostates removed from 440 men. They measured the activity of hundreds of genes thought to be involved in whether the cancer spread beyond the prostate or proved fatal. A second study of biopsies from 167 patients narrowed it down to 81 genes, and researchers picked 17 that seemed to predict aggressiveness no matter the location in the tumor.
A third study used single needle-biopsy samples from 395 UCSF patients scheduled to have their prostates removed. The gene test accurately predicted the aggressiveness of their cancer once doctors were able to see the whole prostate after surgery.
Using one current method, 37 of the 395 men would have been called very low risk and good candidates for monitoring. Adding the gene test put 100 men into that category, said another study leader, Dr. Matthew Cooperberg of UCSF. The gene test shifted about half of the men into either a lower or a higher risk category.
“It went both ways — that was the remarkable thing. In any category of risk it added independent information compared to the standard criteria we use today,” Carroll said. “More work needs to be done, but, in my opinion, this is a very good start.”
However, Dr. Kevin McVary, chairman of urology at Southern Illinois University School of Medicine and a spokesman for the Urological Association, said the test must be validated in more men before it can be widely used.
“It’s not there yet,” he said.
UCSF just got a federal grant to see how men choose treatments and whether this test might sway them.
“We throw all these numbers at them. Are they really going to make a better decision?” Cooperberg said.
Dean Smith, 60, a retired marketing executive from Mill Valley, Calif., is following his doctor’s advice to monitor the cancer he was diagnosed with in March. He said a gene test may have made him more comfortable with that decision.
At least six of his friends suffered side effects ranging from urinary leakage to inability to have sex after having their prostates removed.
“I would suspect that having cancer and having to live with it would be very difficult for them,” but it doesn’t bother him, Smith said. “I will die from something other than prostate cancer, I guarantee you.”
*    *     *

Here’s a link to the American Urological Association’s latest guidelines for the detection of prostate cancer:

Detection of Prostate Cancer

(I’ve added a link to the AUA in the “Helpful Links” section, too.)

Urologists Recommend Less PSA Testing For Prostate Cancer

by Scott Hensley

May 03, 2013 2:49 PM

Terry Dyroff, of Silver Spring, Md., had a PSA blood test that led to a prostate biopsy. The biopsy found no cancer but did give him a life-threatening infection.

The men and women who often treat prostate cancer are now recommending that the blood test commonly used to screen for it should be given a lot less often.

The American Urological Association released new guidelines that, if they’re heeded, would dramatically reduce the ranks of men who would be candidates for PSA testing.
The prostate-specific antigen test can catch cancer early, but it frequently gives false alarms or identifies cancers that don’t require treatment.
So the urology specialists now say this about screening for prostate cancer:
  • Men under 40 shouldn’t get PSA tests.
  • Men ages 40 to 50 shouldn’t be tested, if they’re at average risk for the disease. Those at higher risk — such as African-American men and those with a family history of prostate cancer — should talk it over with their doctors.
  • For men 55 to 69, the test makes the most sense. The AUA panel recommends a shared decision by doctors and patient about the test. Once testing begins, the panel says it should be given every two years, rather than annually.
Finally, the group says men over 70 and with less than a 10 to 15 year life expectancy can probably skip the test.
Johns Hopkins urologist H. Ballentine Carter, chair of the guideline panel, acknowledged to USA Today that some men and doctors may be hesitant about less screening.

But the evidence reviewed by the panel supports the stance. PSA screening can prevent about 1 death from prostate cancer for every 1,000 men screened over a decade, the guideline says. But there are dangers from testing, including false positives and side effects from subsequent testing and treatment, including infections, impotence and incontinence.

“The public is very enthusiastic about screening, partly because of our messaging,” Carter told USA Today. “The idea that screening delivers benefits may have been overexaggerated.”

Almost a year ago the influential U.S. Preventive Services Task Force issued its own guideline saying healthy men should no longer get routine PSA tests.

The urologists disagreed then — and now. But the conversation has now shifted to how few men should get tested instead of how many.

Update at 3:55 p.m. ET: Dr. Otis Brawley, the American Cancer Society’s chief medical officer, and a longstanding critic of PSA testing, praised the urology group’s work in an email to Shots:

“I believe that the American Urological Association should be commended for a very careful evidentiary review and developing a statement that is truly consistent with the state of the science.

“The past 20 years represents some of the worst in public health in that we widely disseminated a screening intervention before adequately assessing it. I welcome any effort to explain to men the uncertainty, potential harms, and potential benefits of PSA screening. Use of this test should be a decision made by the individual patient in collaboration with his healthcare provider. The American Urological Association statement combined with the American College of Physicians statement of last month should mean the end of mass screening for prostate cancer.

“Now the American Cancer Society and five other independent organizations are calling for shared or informed decision making regarding use of this test.”

Month 29 – Blogging About Cancer

On By DanIn Incontinence, Prostate Cancer, Sexual Function, Side Effects, Social Aspects1 Comment

I stumbled across the article below a few weeks ago and found it to be quite interesting, considering that I’ve been blogging about my prostate cancer for over two and a half years and 8,000+ page reads now.

Blogging about cancer certainly isn’t for everyone, and there are concerns in this electronic age.  For example, how much do you want your employer to know about what you’re going through?  How do you protect your own privacy and the privacy of others in your blog?  All things to consider.

I haven’t looked at some of the sites mentioned in any detail, but the one that offers up a calendar to coordinate visits, meals, snow shoveling, etc., is something that could come in quite handy.

During my recuperation, I had very generous friends and neighbors who would help me out, but there was no coordination, and I’d end up with three meals on one night, and go for four or five days without seeing someone.  Would have been nice to have that calendar and the ability to coordinate better.

*     *     *
BIOLOGY AHEAD
Well, last month I reported having had an erection good enough for penetration, and I’m sad to report that, for now, it appears to have been a one-time event. Still, my erections are certainly better than a year ago, and it’s something I’ll discuss with my urologist when I go for my next PSA test in May.

Other than that, things are pretty good… I can sleep 7-8 hours through the night without having to use the bathroom, and I think I’m stuck with some very minor stress incontinence (a drop or two when I cough, sneeze, or squat) from here on out.

*     *     *

Why More Patients Should Blog About Illness and Death

by Eliza Barclay

March 28, 201310:05 AM

I entered the world of illness blogs for the first time when I learned through Facebook that a friend from middle school passed away last Friday from acute myeloid leukemia. In the three months between his diagnosis and his death, the friend, whom I’ll call Tom, blogged beautifully and intimately on CaringBridge, a Web tool designed to help the seriously ill tell their stories and manage communication with friends and family.

Tom was 34. In his Web journal, he wrote about the trauma of bone marrow exams and chemotherapy and his anxiety about finding a bone marrow transplant donor. He supplemented his dispatches from the cancer ward with funny and raw Instagram photos, defiant tweets and YouTube videos and lyrics of the songs he was listening to.

Altogether, it was a window, painful but so rarely accessible, into the exquisite horror of a harrowing prognosis and the burden of the toll of illness on his friends and family. Tom was desperately worried about his wife, his young son and his daughter on the way. Yet his love for them rang out so clearly through his writings that the blog itself may one day be a treasured memento of the ways Tom held them close in his final days.

We share so many milestones now through social media. And that includes health: A 2010 survey by Pew Research found that 23 percent of the users of social networking sites have followed their friends’ personal health experiences on Facebook. So is it any surprise that the outer reaches of our social networks now also deliver us intimate stories of dying?

Palliative care experts, who specialize in improving the quality of life for people with a life-threatening illness, say all this blogging and sharing about illness is helping to open up the conversation about death that we so often avoid.

“As more people tell their story of dying with a terminal illness, we’re seeing a change in how we look at illness and mortality,” says Christian Sinclair, national hospice medical director at Gentiva Health Services, a large home health care company. “Illness and death are still so technically driven, or medicalized. So getting a safe space, like a blog or social media, to talk about it can be very empowering.”

Blogging empowers patients to talk about illness outside the typical frame of “the battle,” Sinclair says, and reading the stories helps family members, too. “They don’t have to dodge the hard questions, because the patient is able to tell their story openly and frankly,” says Sinclair, who also edits the blog Pallimed.

The most prestigious medical institutions, including Johns Hopkins and the University of Michigan, now encourage patients to blog their illness through sites like CaringBridge and CarePages. In the hospice community, a longtime volunteer and software engineer started What Matters Now to offer similar services.

Other institutions, like the Georgetown Lombardi Comprehensive Cancer Center in Washington, D.C., run writing workshops. Nancy Morgan, who directs the center’s arts and humanities program, says she never instructs people to write directly about cancer. “There is a potential for wounding,” she says, especially if the patients are depressed or otherwise feeling too vulnerable. “Most of the time they do [choose to write about the cancer], but it’s their choice.”

While many illness blogs are read only by friends and family, some patients go more public with their stories. Right here on NPR.org, Leroy Sievers and his wife, Laurie Singer Sievers, blogged their way through Leroy’s cancer, which took his life in 2008. And David Oliver, a retired professor of gerontology at the University of Missouri, and his wife, Debbie, a palliative care and hospice expert at the same university, have kept a video blog of David’s illness on YouTube and this site.

Still, some bloggers keep their blogs private from certain people close to them during their illness. A 2011 survey of 41 illness bloggers by researchers at Tufts University School of Medicine found that only 1 in 4 of the writers shared their blogs with their health providers.

Holding back from doctors and nurses like that could be a missed opportunity — and not just for the patient, according to Sinclair. “I think these blogs help physicians and nurses see their patients as [people],” he says. “But there are boundaries, and some health care professionals are looking for opportunities to get closer while others want to shield themselves.”

Sinclair says that when patients have shared their blogs with him, he’s enjoyed them. “I think it helps us check up on our own mortality. Am I doing the things I want to do? Am I making a difference? These are positive questions that can get lost in the shuffle of the day.”

Month 28 – Surprises

On By DanIn Prostate Cancer, Sexual Function, Side EffectsLeave a comment

So this month I had two surprises related to my surgery and its outcome…

The first came in the mail.

Remember that my surgery was on 4 January 2011…  This week I received a bill for the anesthesiologist, which I thought was odd.  I dug through my financial records and found that I paid them back in March of 2011, so I called my insurance provider to see if they had any insight.

It appears that I had more than one person assisting and this was the bill for the second person (that apparently had gotten mired up in some administrative red tape).  I also called the anesthesiologist’s office, and they’re digging into what happened, too.

Lesson learned:  Keep good records of all your health insurance transactions and be ready to question anything.

The second surprise…  Well, it requires my standard “Biology Ahead” warning:

BIOLOGY AHEAD
With only one nerve bundle remaining, my return to full sexual function has been slow. Still, it’s been steadily getting better over the last two years.

This week, I achieved what I would consider to be a full erection good enough for penetrative sex. And that was without any chemical assistance–no Cialis or Viagara!

Once does not a trend make, but it was encouraging to see that the progress continues. Needless to say, I was pleasantly surprised.

So that’s about it for this update. Best of luck to one of my readers as he nears his treatment option decision point. I’m sure he’ll select what’s best for him and his circumstances after doing his research.

Month 27 – Another Study

On By DanIn Prostate Cancer, Research, Side EffectsLeave a comment

New Page & New Helpful Link

You may have noticed that I’ve added a new page (link to the right)–“Life After Radical Prostatectomy – 24 Months Later” for those with inquiring minds…Under the Helpful Links section to the right, I’ve added a link to the American Cancer Society’s list of questions you should ask your doctor during your diagnosis and treatment.

Another Study

So there’s yet another study published in the New England Journal of Medicine (link to original article and text below) talking about the side-effects of prostate cancer treatment, supporting the notion that prostate cancer is overtreated with significant consequences.

I get it. But until researchers can isolate the really agressive cancers from the more slow-growing cancers, it’s a crap shoot for any prostate cancer patient no matter how you slice it. Do the active surveillance and pray that the cancer doesn’t metastasize and spread, or treat it with surgery or radiation and risk possible significant side effects when it could have been left alone.

More research is needed to get us to that point where we can make truly educated decisions about our treatment options based on whether we confirmed we have the aggressive or slow-growing cancer.

Would I have made a different treatment decsion two years ago if I had known this information? Probably not. I take comfort in knowing that my PSA levels have been undetectable for two years now. I don’t know how I would have handled living with cancer in my body under active surveillance, not knowing if and when it would have metastasized.

Prostate cancer treatments have serious long-term side effects

Prostate cancer treatments have serious long-term side effects

By Robert Bazell, Chief Science and Health Correspondent

New research strongly reinforces the notion that prostate cancer is vastly overtreated with often dire results.

A study out Wednesday in the New England Journal of Medicine focused on treatment side effects, following a group of 3,533 men for 15 years after they got either surgery (called prostatectomy) or radiation for cancer that had not spread beyond the prostate. Radiation produced fewer side effects — especially in the first years after treatments– but both groups experienced huge impacts.

“This paper tells you that if you get treatment there are a lot of side effects regardless of the therapy you chose,” the senior author Dr. David Penson, professor of urologic surgery at Vanderbilt University Medical Center, said in an interview.

Most men were in their sixties when they were first treated. Two years after treatment 60.8 percent of the men who had undergone radiation had erectile dysfunction, compared to 78.8 percent of those who chose surgery. By 15 years, the numbers became 87 percent and 93.9 percent. Many men also suffered urinary and bowel problems and those, too, grew worse with time.

A rational argument is that such side effects are acceptable if the treatment is saving lives. But the paper raises serious doubts.

“So many of these men have low-risk disease that probably doesn’t need to be treated,” Penson said.

Men typically undergo needle biopsies because they have elevated levels of the blood test called prostate-specific antigen (PSA). If the needle finds cancer cells, a pathologist measures their severity, resulting in what is called a combined Gleason score that ranges from 1– the least severe– to 10.

Most prostate cancers score between 6-7. Several top urologists at university medical centers agreed that prostate cancer below a score of 6 should be watched, but not treated. Yet in this latest study, which is a reliable cross-section of how medicine is actually practiced, about 60 percent of the men who underwent treatment had scores of 2 to 4.

The findings prove that “a staggering percentage of men with totally inconsequential prostate cancer got treated and suffered the consequences,” says oncologist Dr. Marc Granick of Beth Israel Deaconess Medical Center and Harvard Medical School, who was not involved the study.

Undoubtedly, prostate cancer can be deadly. Estimates are that it will kill almost 30,000 men in the United States this year, second only to lung disease as the major cause of cancer deaths in men. But the problem is, there are at least two kinds of prostate cancer.

The common form appears in the majority of men over age 50, grows slowly, and never presents a health threat. The other form spreads rapidly and can lead to a horribly painful death, usually from malignant cells invading the bones. Doctors cannot tell the difference between the dangerous and harmless cancers. Researchers are looking for genetic markers that would make the critical distinction, but they have yet to find them.

Meanwhile, increasing numbers of prostate cancer specialists argue that the sensible path is for men with lower combined Gleason scores to undergo active surveillance (formerly called watchful waiting), come back for future tests and forgo treatment until it is indicated. Often they will never need treatment.

That doesn’t happen, however. Penson said recent surveys show that fewer than one in four men who are candidates gets active surveillance. The majority get surgery or radiation.

One reason for the intervention is “incentives for the facility and for the providers” — in other words, money for hospitals and doctors. “Also,” he adds, “patients don’t like to hear ‘I have cancer and I’m just going to watch it.’” But patients should demand and doctors should educate that “just watching it” is perfectly safe in many cases.

Learning that lesson could spare an enormous amount of misery and money.

Month 26 – Two Down; Eight to Go; and 55

On By DanIn Incontinence, Prostate Cancer, Side Effects, Social AspectsLeave a comment

Okay. First, a warning. This month’s update will be like a ping pong ball in a clothes drier– topics all over the place.

Two Down; Eight to Go

For family, friends, and regular blog readers, you know that I can get pretty OCD about remembering dates and anniversaries. Well, imagine my own surprise when Friday, 1/4, came and went as though it were a regular day, and it was.

But it was two years ago Friday that I was having that pernicious little prostate plucked from my pelvis in surgery, and I completely forgot about it! I guess that’s a good sign. Life goes on after prostate cancer. That, or perhaps my memory is fading… 😦

Most will say that you have to remain cancer-free for 10 years to really have beaten it, so Friday marked 2 years down, 8 to go.

55

Somewhere between last month’s post and this month’s post, I celebrated my 55th birthday. My new motto regarding birthdays–regardless of the number–is: Any birthday you’re around to celebrate is a great birthday!

Blog Reader Visits

This week, I visited with two guys who I’ve met through this blog. Kind of building a mini-support network, I guess.

One had his radical prostatectomy in May 2012 and is progressing nicely. The other just began this journey with his prostate cancer diagnosis last Friday. I wish him well.

BIOLOGY AHEAD

Jinxed

Wouldn’t you know it? After writing last month’s post about sleeping through the night, I’ve been having problems sleeping through the night. Go figure.

When I was staying with my sister for the holidays, two of the five nights I was there, I was up peeing four or five times through the night. My fluid intake wasn’t any higher than normal. (Really! No 12 pack of holiday beer or gallon of eggnog…) In fact, the one night, I was beginning to wonder, “Where is all this coming from?!?” I’ve had a couple nights since where I’ve been up two or three times.

PCa and Dating

My gut tells me that I’m in a tiny group of prostate cancer (PCa) survivors who are single. The vast majority of PCa survivors are already in relationships, and their spouses/partners were part of the treatment decision-making process, fully understanding the risks and possible side effects when it came to sexual function.

One of my New Year’s resolutions was to throw myself into the deep end of the dating pool because I really would like to share my life with someone.

My struggle, however, is figuring out how and when to tell that someone about the PCa, the surgery, and its impact on my sexual function.

With only one nerve bundle remaining, I can only achieve a 50% – 75% erection–not enough for penetrative sex. And, of course, when I orgasm, there is no ejaculate–zip, zilch, nada.

Relationships should be founded upon open, honest communication. But somehow I don’t think I’ll swim even one lap in the dating pool if I walk into the restaurant and say, “Hi. Pleased to meet you. I can’t get a boner and I don’t ejaculate. Still wanna try this out?”

Nor do I want to string someone along for weeks or months and then find that romantic moment where things would progress to the next level and have to say, “You know… There’s something I’ve been meaning to tell you,” or, worse, “Surprise!!”

Relationships are more than just sex (and intimacy is more than just intercourse). So part of me says let the person get to know me over a period of time, and if there’s a real connection, then they may be able to overlook the sexual function issues. But if it is an issue, then there may be two broken hearts as we head off in separate directions.

Somewhere in the middle may be best. Perhaps in the 3-5 date range. If it looks like there’s a possibility that this may go someplace, let them know at that point. They’ll know enough about me to make the call as to whether my dashing good looks , charming personality, and quirky wit outweigh the sexual function shortcomings.

So wish me luck.

Life After Radical Prostatectomy: 24 Months Later

On By DanIn Life After Prostatectomy, Prostate CancerLeave a comment

So it’s been two years since my radical prostatectomy, and I think that things have plateaued for me.

There really hasn’t been any significant change in my status since writing my 18-month update.

Continue reading “Life After Radical Prostatectomy: 24 Months Later” →

Month 25 – Sleeping through the night

On By DanIn Incontinence, Prostate Cancer, Side EffectsLeave a comment

Not long ago, I was comparing notes with a fellow radical prostatectomy patient, and the discussion led to sleeping through the night.

This particular gentleman said that, while he had nearly 100% control over incontinence, the one thing that plagued him was the need to run to the bathroom multiple times through the night.  Obviously, that makes for a very fitful sleep pattern.

My own experience has been much better.  In the first few months after my surgery, I was running to the bathroom 2-4 times through the night.  I suspect, though, that was me being overly cautious, not wanting to have an accident in the bed.  I would also curtail my fluid intake after dinner with the thought that, if there’s nothing in me, there’s nothing that will have to come out.

Today, I can pretty much sleep through the entire night without a problem, even with late night fluid intake (I gave up on the nothing-to-drink-after-dinner notion long ago).  Still, there’s probably one night every six weeks or so where I find myself making two or three trips for whatever reason.  But it’s happened the last few nights, but I suspect that may be something related to recovering from my first overseas trip since the surgery.

I just came back from a trip to Germany and Austria to check out the Christmas markets and to visit family and a friend.  I think my body clock is still somewhere between Vienna and here, and that’s why I’ve had to run to the bathroom in the middle of the night.  Pure speculation.

The flights over and back went just fine.  No problems with being cooped up for 9 hours or so, at least as far as bladder control was concerned.  I did pack a couple of pads for insurance, but all they did was take up a little suitcase space.  They weren’t needed at all.